Diabetic Cataract Drug Development Services
With the increasing incidence of diabetes and the development of aging, as well as the higher risk of surgical and postoperative complications of diabetic patients undergoing surgery, it is still necessary to study the occurrence and development mechanism of diabetic cataracts as well as potential therapeutic targets and therapeutic drugs. At Ace Therapeutics, we focus on providing integrated support for innovative therapy development, encompassing target discovery, drug screening, and preclinical validation to accelerate the advancement of breakthrough treatments.
Pathogenic Mechanisms and Emerging Therapeutic Opportunities for Diabetic Cataracts
The high prevalence and pathologic complexity of diabetic cataracts pose a challenge for drug development. Recent studies have revealed core pathologic mechanisms that point the way to the development of innovative therapies.
- Imbalance of aqueous humor metabolism: disruption of the lens microenvironment.
- Oxidative stress and ROS burst: irreversible protein damage.
- Polyol pathway hyperactivation: sorbitol accumulation osmotic pressure imbalance.
- Abnormal non-coding RNA regulation: gene network cascade dysregulation.
- Dysregulation of aqueous humor metabolism: Elevated glucose concentration in aqueous humor drives lens cell edema, and sorbitol transporter (SLC2A1) becomes a key regulatory node.
- Oxidative stress cascade: increased reactive oxygen species (ROS) production leads to oxidative damage of lens proteins and Nrf2 antioxidant pathway activators as potential targets for intervention.
Inhibitors or drugs target to these processes, such as aldose reductase inhibitors, antioxidants, natural flavonoid compounds, as well as nanotechnology-based therapeutic product, have shown promising prospects in the prevention and treatment of diabetic cataract.
Our Diabetic Cataract Drug Development Services
Ace Therapeutics provides comprehensive solutions for the preclinical development of diabetic cataract drugs, delivering critical data support for the efficacy and safety evaluation of candidate drugs.
Target Discovery and Validation Services for Diabetic Cataracts
- Differential gene/protein screening.
- Non-coding RNA-mRNA regulatory network construction.
- Key pathway analysis of polyol, Nrf2/ARE, apoptosis signaling.
Lead Compound Development Services
- High-throughput screening of aldose reductase inhibitors.
- Natural compound library active ingredient mining (flavonoids/phenolic acids).
- Nanocarrier design (liposome/dendrimer targeted delivery).
Preclinical Efficacy and Safety Assessment Services
- In vitro model: high glucose induced lens epithelial cell/ organoid model
- In vivo model: STZ-induced diabetic rat/mouse, spontaneous db/db diabetes model
- Evaluation System:
- Lens transparency quantification (Scheimpflug imaging)
- Oxidative damage marker assay (SOD/GSH/MDA)
- Protein post-translational modification analysis (glycosylation/ubiquitination)
Technology Platform in Our Diabetic Cataract Drug Development Services
Leveraging advanced technology platforms and interdisciplinary approaches, we aim to help clients translate cutting-edge scientific insights into viable drug candidates.
| Technology Platforms |
Core Equipment |
Testing Content |
| In vivo testing |
Small animal slit lamp microscope |
Dynamic monitoring of lens turbidity |
| Histopathology analysis |
Automatic tissue dehydration and embedding machine |
Lens fiber cell morphology |
| Molecular mechanisms study |
Laser confocal microscope |
Localization of AGEs deposition sites in the lens fiber interstitial space |
| Multi-omics analysis |
High resolution mass spectrometer |
Identify sites of glycosylation modification of lens proteins |
Why Choose Ace Therapeutics?
- Targeting core mechanisms
Deliver comprehensive solutions from molecular screening to preclinical development for disease pathways including aqueous humor metabolism and oxidative stress.
Accelerate drug development through AI-driven drug design and integrated preclinical testing.
Reduce attrition rates with early toxicity prescreening and dual-model validation (in vitro/in vivo).
Ace Therapeutics offers a one‑stop, high‑translation solution from target discovery to preclinical evaluation. Contact our expert team today to receive a customized proposal and project assessment.
Reference
- Li Y, Pan A P, Yu A Y. Recent Progression of Pathogenesis and Treatment for Diabetic Cataracts[C]//Seminars in ophthalmology. Taylor & Francis. 2025, 40(4): 275-282.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
